Back to News

PacBio announces appointment of David Ruggiero as Head of Global Sales & Service


Menlo Park, California, USA
February 3, 2025

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company’s new Global Head of Sales & Service.

Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom Video Communications, Microsoft Corporation, and Thermo Fisher Scientific, where, as part of Life Technologies, he was Chief Commercial Officer for the Life Sciences Solutions Group.

“We are thrilled to welcome David to the PacBio team,” said Christian Henry, President and CEO of PacBio. “His extensive experience and proven track record in creating and leading high-performing sales teams in both technology and life sciences make him an ideal fit as we continue to seek to expand our global presence and deliver innovative sequencing solutions to our customers.”

In his new role, Mr. Ruggiero will oversee PacBio’s global sales and service operations, focusing on accelerating the adoption of the company’s sequencing platforms and enhancing customer support worldwide.

“I am excited to join PacBio at such a pivotal time in the company’s growth,” said Mr. Ruggiero. “I look forward to working with the team to build on PacBio’s strong foundation and drive further success in bringing cutting-edge sequencing technologies to researchers and clinicians around the world.”

Mr. Ruggiero is expected to start on February 10, 2025.

 



More news from: PacBio - Pacific Biosciences of California, Inc.


Website: http://www.pacb.com/

Published: February 5, 2025